Eliminating downstream bottlenecks and boosting productivity in antibody-based therapies

Overview

The monoclonal antibody (mAb) manufacturing industry is looking for ways to reduce expenses, and one of the most costly items for mAb production is resin materials for purification. Developers working within an aggressive timeline need new ways to optimize their downstream strategy without compromising product quality. This article covers how a new type of single-use technology for downstream purification may be the key to creating efficiencies never seen before. 

Key Takeaways

• An overview of the new single-use membrane device technology vs. packed bed resin-based protein capture

• The benefits of single-use membrane capture technology to developers and CDMOs

• Opportunities for this technology to build new efficiencies via by offering a true full single-use downstream process